Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Hemangioblastoma


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview

What is a hemangioblastoma?

What causes hemangioblastoma?

Is genetic testing available for hemangioblastoma?

How might a hemangioblastoma be treated?

What is a hemangioblastoma?

A hemangioblastoma is a benign, highly vascular tumor that can occur in the brain, spinal cord, and retina (the light-sensitive tissue that lines the back of the eye). This tumor accounts for about 2% of brain tumors. As it enlarges, it presses on the brain and can cause neurological symptoms, such as headaches, weakness, sensory loss, balance and coordination problems, and/or hydrocephalus (a buildup of spinal fluid in the brain). Most hemangioblastomas occur sporadically. However, some people develop hemangioblastomas as part of a genetic syndrome called von Hippel-Lindau syndrome. These people usually develop multiple tumors within the brain and spinal cord over their lifetime.[1][2]
Last updated: 7/5/2011

What causes hemangioblastoma?

Most hemangioblastomas rise sporadically, without a known cause. However, in about one quarter of all cases, they are associated with von Hippel-Lindau (VHL) syndrome.[2] VHL is an inherited condition characterized by the abnormal growth of tumors in certain parts of the body. The specific tumors that are associated with VHL syndrome include hemangioblastomas of the brain, spinal cord, and retina; kidney cysts and clear cell kidney cell carcinoma; pheochromocytomas; and endolymphatic sac tumors. Mutations in the VHL gene cause von Hippel-Lindau syndrome. These mutations are inherited in an autosomal dominant pattern.[3]
Last updated: 7/5/2011

Is genetic testing available for hemangioblastoma?

Although the exact cause of hemangioblastoma is unknown, its presence in various clinical syndromes may suggest an underlying genetic abnormality. The genetic hallmark of hemangioblastomas is the loss of function of the VHL gene.[2]

GeneTests lists the names of laboratories that are performing genetic testing for von Hippel-Lindau syndrome. To view the contact information for the clinical laboratories conducting testing, click herePlease note:  Most of the laboratories listed through GeneTests do not accept direct contact from patients and their families; therefore, if you are interested in learning more, you will need to work with a health care provider or a genetics professional.  Below, we provide a list of online resources that can assist you in locating a genetics professional near you.
Last updated: 7/5/2011

How might a hemangioblastoma be treated?

Surgery is considered the standard treatment for hemangioblastoma and usually cures this condition.[2] Following surgery, individuals who have had a hemangioblastoma should continue to visit their physician regularly for physical examinations and magnetic resonance imaging (MRI) of the brain.[2][4] These suggested guidelines for follow-up after hemangioblastoma do not state how frequently physician visits or MRIs should be.
Last updated: 1/16/2014

References
  1. Hemangioblastoma. Genetics Home Reference. June 2011; http://ghr.nlm.nih.gov/glossary=hemangioblastoma. Accessed 7/5/2011.
  2. Slavin KV & Wyler AR. Hemangioblastoma. eMedicine. May 2011; http://emedicine.medscape.com/article/250670-overview#showall. Accessed 7/5/2011.
  3. Von Hippel-Lindau Syndrome. Genetics Home Reference (GHR). July 2008; http://ghr.nlm.nih.gov/condition/von-hippel-lindau-syndrome. Accessed 7/5/2011.
  4. National Comprehensive Cancer Network. Central Nervous System Cancers. NCCN Clinical Practice Guidelines in Oncology. 2013; Version 2.2013:PSCT-2, PSCT-4. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 1/16/2013.


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.